We have put together a stellar editorial board which will continue to expand to assist us in guiding our new publication and to provide a vision for our future editorial coverage.
We know it is an extremely exciting time to be a retinal specialist, and we share your enthusiasm for this field. We will pack our issues with the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. We will call on the most well-respected specialists to weigh in on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.
Each issue will keep you up to date on clinical trials in progress and will also include a free continuing medical education activity. We will strive to keep you on the forefront of the latest technological advances.
We are excited to bring you this first issue with a focus on diseases of the macula. Michael S. Ip, MD, has provided a comprehensive overview for this cover focus: He takes a look at the future of central retinal vein occlusion, branch retinal vein occlusion and diabetic macular edema therapies.
Narrowing things down to more specific treatment strategies, Robert L. Avery, MD; and Dante J. Pieramici, MD, explore the use of bevacizumab in the treatment of ocular disease. Peter K. Kaiser, MD; and Rishi P. Singh, MD, provide a look at the anti-vascular endothelial growth factor treatments that have revolutionized age-related macular edema (AMD) therapy. Nancy Holekamp, MD, reminds surgeons to be cautious when using off-label intravitreal steriod injections as a treatment.
To round out the special focus, we take a look at some demographic data on AMD from the second examination of the MESA, as well as the latest pegaptanib data presented at the recent Macula Society meeting.
Please feel free to contact us with any questions, concerns or article ideas. Look for our staff at the next scientific meeting and introduce yourself! We want to hear from our readers.